Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotic-Free future: study tests stopping trachoma treatment

NCT ID NCT04185402

Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether it is safe to stop giving annual azithromycin to communities with low levels of trachoma, an eye infection that can cause blindness. Over 3,900 people in Niger took part. Researchers compared stopping treatment after at least 5 years versus continuing for 3 more years to see if the infection would stay under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

3,931 people

The number who actually took part.

Started

May 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 month and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of appropriate informed consent * Stated willingness to comply with all study procedures * Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial Exclusion Criteria: * Does not consent to participation * Unwilling to comply with all study procedures * Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Trachoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

trachoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Trachoma

Contacts and locations

Locations

  • Programme National de Santé Oculaire (PNSO)

    Niamey, Niger

More trials for these conditions

Other studies related to the condition(s) this trial covers.